Pfizer Inc.

SNSE:PFE Stock Report

Market Cap: US$146.2b

Pfizer Valuation

Is PFE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PFE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$57.45
Fair Value
54.6% undervalued intrinsic discount
24
Number of Analysts

Below Fair Value: PFE ($26.06) is trading below our estimate of fair value ($57.45)

Significantly Below Fair Value: PFE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PFE?

Key metric: As PFE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PFE. This is calculated by dividing PFE's market cap by their current earnings.
What is PFE's PE Ratio?
PE Ratio14.9x
EarningsUS$9.80b
Market CapUS$146.18b

Price to Earnings Ratio vs Peers

How does PFE's PE Ratio compare to its peers?

The above table shows the PE ratio for PFE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.2x
SAN Sanofi
16.3x11.96%€104.5b
BMY Bristol-Myers Squibb
16.6x4.57%US$100.3b
4519 Chugai Pharmaceutical
34.6x10.54%JP¥13.9t
GSK GSK
13.2x8.69%UK£72.4b
PFE Pfizer
14.9x1.34%US$146.2b

Price-To-Earnings vs Peers: PFE is good value based on its Price-To-Earnings Ratio (14.9x) compared to the peer average (20.2x).

Price to Earnings Ratio vs Industry

How does PFE's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

21 CompaniesPrice / EarningsEstimated GrowthMarket Cap
PFE 14.9xIndustry Avg. 22.7xNo. of Companies94PE01632486480+
21 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PFE is good value based on its Price-To-Earnings Ratio (14.9x) compared to the Global Pharmaceuticals industry average (22.7x).

Price to Earnings Ratio vs Fair Ratio

What is PFE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PFE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PFE's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PFE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$26.06
US$29.04
+11.43%
13.20%US$36.16US$24.00n/a24
Nov ’26US$26.06
US$28.75
+10.33%
12.26%US$36.00US$24.00n/a21
Oct ’26US$26.06
US$28.90
+10.92%
12.17%US$36.00US$24.00n/a21
Sep ’26US$26.06
US$28.77
+10.41%
12.79%US$38.00US$24.00n/a22
Aug ’26US$26.06
US$28.67
+10.03%
12.99%US$37.80US$23.00n/a22
Jul ’26US$26.06
US$29.24
+12.20%
16.90%US$42.00US$23.00n/a23
Jun ’26US$26.06
US$29.24
+12.20%
16.90%US$42.00US$23.00n/a23
May ’26US$26.06
US$29.25
+12.23%
16.01%US$42.00US$23.00n/a22
Apr ’26US$26.06
US$31.26
+19.95%
13.83%US$42.00US$25.00n/a21
Mar ’26US$26.06
US$31.04
+19.11%
12.53%US$42.00US$25.00n/a21
Feb ’26US$26.06
US$31.13
+19.45%
12.24%US$42.00US$25.00n/a22
Jan ’26US$27.95
US$31.86
+14.00%
14.51%US$45.00US$25.00n/a23
Dec ’25US$27.95
US$32.66
+16.85%
13.84%US$45.00US$25.00n/a23
Nov ’25US$27.95
US$33.41
+19.53%
13.09%US$45.00US$27.00US$26.0623
Oct ’25US$27.95
US$33.56
+20.09%
13.35%US$45.00US$27.00US$26.0622
Sep ’25US$27.95
US$33.23
+18.90%
13.03%US$45.00US$27.00US$26.0622
Aug ’25US$27.95
US$32.87
+17.60%
13.81%US$45.00US$27.00US$26.0622
Jul ’25US$27.95
US$31.92
+14.19%
15.07%US$45.00US$27.00US$26.0622
Jun ’25US$28.90
US$31.92
+10.43%
15.07%US$45.00US$27.00US$26.0622
May ’25US$26.92
US$31.62
+17.46%
15.43%US$45.00US$26.00US$26.0622
Apr ’25US$26.92
US$32.70
+21.48%
18.62%US$50.00US$26.00US$26.0622
Mar ’25US$29.80
US$32.71
+9.78%
18.40%US$50.00US$26.00US$26.0623
Feb ’25US$29.80
US$33.00
+10.75%
19.27%US$50.00US$26.00US$26.0622
Jan ’25US$29.80
US$33.05
+10.91%
19.89%US$50.00US$23.00US$27.9522
Dec ’24US$29.80
US$40.41
+35.62%
23.06%US$75.00US$32.00US$27.9522
Nov ’24US$34.04
US$40.91
+20.19%
22.45%US$75.00US$32.00US$27.9522
US$29.43
Fair Value
11.5% undervalued intrinsic discount
24
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/28 14:24
End of Day Share Price 2025/11/27 00:00
Earnings2025/09/28
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pfizer Inc. is covered by 47 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Kerry HolfordBerenberg
Luisa HectorBerenberg